🇺🇸 FDA
Patent

US 8920799

Methods of treating cancer by administering an Axl ligand-binding portion of an Axl tyrosine kinase receptor extracellular domain

granted A61PA61P35/00A61P35/02

Quick answer

US patent 8920799 (Methods of treating cancer by administering an Axl ligand-binding portion of an Axl tyrosine kinase receptor extracellular domain) held by The Regents of the University of Colorado, a Body Corporate expires Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Dec 30 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 25 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61P, A61P35/00, A61P35/02, A61P7/00